A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women

被引：551

作者：

Bekker, PJ

Holloway, DL

Rasmussen, AS

Murphy, R

Martin, SW

Leese, PT

Holmes, GB

Dunstan, CR

DePaoli, AM

机构：

[1] Amgen Inc, Thousand Oaks, CA 91320 USA

[2] Quintiles, Lenexa, KS USA

[3] SFBC Int Inc, Miami, FL USA

[4] ANZAC Res Inst, Concord, NSW, Australia

来源：

JOURNAL OF BONE AND MINERAL RESEARCH | 2004年 / 19卷 / 07期

关键词：

RANKL; osteoprotegerin; osteoporosis; bone resorption; AMG; 162;

D O I：

10.1359/JBMR.040305

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The safety and bone antiresorptive effect of a single subcutaneous dose of AMG 162, a human monoclonal antibody to RANKL, was investigated in 49 postmenopausal women. AMG 162 is a potent antiresorptive agent for diseases such as osteoporosis.

引用

页码：1059 / 1066

页数：8

共 50 条

[21] Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint
Haynes, DR
Crotti, TN
Loric, M
Bain, GI
Atkins, GJ
Findlay, DM
[J]. RHEUMATOLOGY, 2001, 40 (06) : 623 - 630
[22] The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis
Haynes, DR
Crotti, TN
Potter, AE
Loric, M
Atkins, GJ
Howie, DW
Findlay, DM
[J]. JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME, 2001, 83B (06): : 902 - 911
[23] Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord
Honore, P
Luger, NM
Sabino, MAC
Schwei, MJ
Rogers, SD
Mach, DB
O'Keefe, PF
Ramnaraine, ML
Clohisy, DR
Mantyh, PW
[J]. NATURE MEDICINE, 2000, 6 (05) : 521 - 528
[24] Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis
Hughes, AE
Ralston, SH
Marken, J
Bell, C
MacPherson, H
Wallace, RGH
van Hul, W
Whyte, MP
Nakatsuka, K
Hovy, L
Anderson, DM
[J]. NATURE GENETICS, 2000, 24 (01) : 45 - 48
[25] Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women -: Three-year data from 2 double-blind, randomized, placebo-controlled trials
Johnston, CC
Bjarnason, NH
Cohen, FJ
Shah, A
Lindsay, R
Mitlak, BH
Huster, W
Draper, MW
Harper, KD
Heath, H
Gennari, C
Christiansen, C
Arnaud, CD
Delmas, PD
[J]. ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (22) : 3444 - 3450
[26] Ju HSJ, 1997, CLIN CHEM, V43, P1570
[27] RANK ligand is a prerequisite for cancer-associated osteolytic lesions
Kitazawa, S
Kitazawa, R
[J]. JOURNAL OF PATHOLOGY, 2002, 198 (02) : 228 - 236
[28] Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand
Kong, YY
Feïge, U
Sarosi, I
Bolon, B
Tafuri, A
Morony, S
Capparelli, C
Li, J
Elliott, R
McCabe, S
Wong, T
Campagnuolo, G
Moran, E
Bogoch, ER
Van, G
Nguyen, LT
Ohashi, PS
Lacey, DL
Fish, E
Boyle, WJ
Penninger, JM
[J]. NATURE, 1999, 402 (6759) : 304 - 309
[29] OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis
Kong, YY
Yoshida, H
Sarosi, I
Tan, HL
Timms, E
Capparelli, C
Morony, S
Oliveira-dos-Santos, AJ
Van, G
Itie, A
Khoo, W
Wakeham, A
Dunstan, CR
Lacey, DL
Mak, TW
Boyle, WJ
Penninger, JM
[J]. NATURE, 1999, 397 (6717) : 315 - 323
[30] OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats
Kostenuik, PJ
Capparelli, C
Morony, S
Adamu, S
Shimamoto, G
Shen, V
Lacey, DL
Dunstan, CR
[J]. ENDOCRINOLOGY, 2001, 142 (10) : 4295 - 4304

← 1 2 3 4 5 →